GAM
NUVB icon

Gotham Asset Management’s Nuvation Bio NUVB Stock Holding History

Gotham Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-31,269
Closed -$280K – 1830
2025
Q4 		$280K Buy
31,269
+14,204
+83% +$88K ﹤0.01% 1583
2025
Q3 		$63.1K Buy
+17,065
New +$46.5K ﹤0.01% 1663

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gotham Asset Management's NUVB Position: Q1 2026 in Review

Gotham Asset Management sold out of Nuvation Bio (NUVB) in Q1 2026, closing a stake of 31,269 shares — an estimated $280K sold.

Gotham Asset Management first reported a position in NUVB in Q3 2025 and held it in 2 quarters. The position peaked at $280K in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Gotham Asset Management reported no remaining Nuvation Bio position as of Q1 2026 after selling out during the quarter.
  • Gotham Asset Management sold 31,269 Nuvation Bio shares in Q1 2026, an estimated $280K.
  • Gotham Asset Management first reported a position in Nuvation Bio in Q3 2025 and held it in 2 quarters.
  • Gotham Asset Management's Nuvation Bio position peaked at $280K in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Gotham Asset Management's 13F filing for Q1 2026, filed 15 May 2026.